Aoxing Pharmaceutical Company (AOXG) Fair Value & Analysis
Financial Services · US · Market cap $1.5M
Aoxing Pharmaceutical Company
AOXG · US
Fair value as of: Jun 26, 2026
From 10 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0300 to $0.0041 (−86.4%) since Jun 24, 2026. Share price −2.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0033 – $0.0107 · the $0.0041 price screens above the $0.0041 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aoxing Pharmaceutical Company (AOXG) currently trades at $0.0041, while our model-based Fair Value estimate is $0.0041 — implying the stock looks roughly 0.3% overvalued today. We read business quality at 35/100 (below-average quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Aoxing Pharmaceutical Company generated revenue of $30.1M at a net margin of -4.9%. Revenue declined 13.1% year over year. It earns a return on equity of -7.6%. Net debt stands at $18.6M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II …
Revenue & earnings trend
FY2012 – FY2025 · reported fiscal years
Aoxing Pharmaceutical Company reported revenue of $32.3M in FY2016 versus $8.1M in FY2012, a compound +41.2%/yr. Reported net income was $55.2K in FY2025.
Is AOXG fairly valued? → Check now
Similar stocks
6 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$27.96 | C$11.59 | -59% |
| Lionheart III Corp LION | $15.21 | $14.33 | -6% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.43 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0330 | $0.0500 | +52% |
| GP-Act III Acquisition Corp GPAT | $10.88 | $4.30 | -60% |
| Berto Acquisition Corp TACO | $10.40 | $11.08 | +7% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Aoxing Pharmaceutical Company (AOXG) undervalued?
What is the fair value of AOXG?
What is the quality score of AOXG?
What is the revenue of Aoxing Pharmaceutical Company (AOXG)?
What is the net profit margin of AOXG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.